Schizophrenia is a Chronic, Severe and Disabling Mental DisorderAffecting 2.4 million Americans
Novartis announced that Fanapt(TM) (iloperidone), the company'sschizophrenia treatment, is now available for use across the US. Fanapt is atwice-daily, oral antipsychotic, approved by the US Food and DrugAdministration (FDA) in May 2009 for the acute treatment of schizophrenia inadults.
Schizophrenia is a chronic, severe and disabling mental disorder,affecting 2.4 million Americans. Despite the availability of several agentsfor treatment, as many as 74% of all patients discontinue their medicationbefore completing 18 months of treatment. People with schizophrenia havevarying levels of response and tolerance to available therapies. More than aquarter of patients change their medications within a year, with a mean timeto switching of 100 days.
Fanapt is indicated for the acute treatment of schizophrenia in adults.In clinical trials treatment with Fanapt resulted in significant improvementin symptoms of schizophrenia as demonstrated on two major scales formeasuring the positive and negative symptoms of the disorder.
NEWS: Fanapt Proven Effective for the Treatment of Schizophrenia inAdults - Despite Available Medications, There Remains a Need for AdditionalTreatment Options
FORMAT: B-roll and Soundbites
ADDITIONAL RESOURCES: Video, contact information and more available at:http://multivu.prnewswire.com/broadcast/41920/press.html
VIDEO PROVIDED BY: Novartis Pharmaceuticals Corporation
Contact: FOR MORE INFORMATION, PLEASE CALL: MultiVu Media Relations,1-800-653-5313 EXT. 3SATELLITE FEEDS: Monday, January 11th, 2010 Monday, January 11th, 2010 3:30 AM - 3:45 AM ET 1:15 PM - 1:30 PM ET Galaxy 19 AMC 3 C-Band C-Band Transponder 20 Transponder 3 Downlink Freq. 4100 Horizontal Downlink Freq. 3760 Horizontal
SOURCE Novartis Pharmaceuticals Corporation